Elliott Targets Bio-Rad as Shares Continue to Struggle 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
Samsung Strike Talks Resume as South Korea Weighs Emergency Action 
Alibaba Stock Surges After Strong Q4 Earnings Boosted by AI and Cloud Growth 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Elon Musk’s China Influence Faces New Challenges Amid Rising EV Competition 
SoftBank Shares Slide Despite Record Q4 Profit Fueled by OpenAI Investment 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
Nvidia’s China AI Chip Sales Remain Frozen Despite U.S. Approval 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Asia-Pacific Banks Brace for Rising Credit Risks Amid Iran Conflict 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
WATERTOWN, Mass., Sept. 22, 2016 -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced today that Nancy Lurker, the Company’s newly-appointed President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, September 27, 2016 at 1:30 pm. ET. The conference will be held at the Sofitel Hotel in New York City.
The presentation will be webcast at http://wsw.com/webcast/ladenburg2/psdv and a link will also be available at the Company's website.
About pSivida Corp. pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release drug delivery products primarily for eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the United States and three E.U. countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida’s lead product candidate, Medidur™, a micro-insert for posterior uveitis being independently developed, is currently in pivotal Phase 3 clinical trials, with an NDA anticipated in 2017. pSivida’s pre-clinical development program is focused on using its core platform technologies Durasert™ and Tethadur™ to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+.
Contact: EVC Group Michael Polyviou/Doug Sherk – Investors [email protected]; [email protected] 212.850.6020; 415.652.9100
